Penbrook Management’s Exagen XGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $91.9K | Buy |
+11,300
| New | +$72.6K | 0.05% | 100 |
|
|
2026
Q2 | – | Sell |
-13,330
| Closed | -$40K | – | 103 |
|
|
2026
Q1 | $40K | Sell |
13,330
-100
| -0.7% | -$387 | 0.03% | 93 |
|
|
2025
Q4 | $81.7K | Sell |
13,430
-6,480
| -33% | -$59K | 0.06% | 95 |
|
|
2025
Q3 | $219K | Hold |
19,910
| – | – | 0.15% | 87 |
|
|
2025
Q2 | $139K | Sell |
19,910
-19,455
| -49% | -$118K | 0.1% | 92 |
|
|
2025
Q1 | $141K | Sell |
39,365
-5,229
| -12% | -$19.7K | 0.11% | 100 |
|
|
2024
Q4 | $183K | Sell |
44,594
-18,361
| -29% | -$66.2K | 0.12% | 100 |
|
|
2024
Q3 | $195K | Sell |
62,955
-6,500
| -9% | -$16.8K | 0.13% | 96 |
|
|
2024
Q2 | $126K | Sell |
69,455
-7,255
| -9% | -$12.3K | 0.08% | 98 |
|
|
2024
Q1 | $122K | Buy |
76,710
+1,000
| +1% | +$1.94K | 0.08% | 101 |
|
|
2023
Q4 | $151K | Buy |
75,710
+2,300
| +3% | +$3.98K | 0.1% | 96 |
|
|
2023
Q3 | $178K | Sell |
73,410
-600
| -0.8% | -$1.52K | 0.13% | 91 |
|
|
2023
Q2 | $215K | Hold |
74,010
| – | – | 0.16% | 88 |
|
|
2023
Q1 | $180K | Hold |
74,010
| – | – | 0.14% | 89 |
|
|
2022
Q4 | $178K | Sell |
74,010
-12,990
| -15% | -$33.3K | 0.15% | 89 |
|
|
2022
Q3 | $236K | Sell |
87,000
-1,100
| -1% | -$6.14K | 0.2% | 85 |
|
|
2022
Q2 | $506K | Sell |
88,100
-500
| -0.6% | -$2.91K | 0.4% | 66 |
|
|
2022
Q1 | $711K | Hold |
88,600
| – | – | 0.46% | 62 |
|
|
2021
Q4 | $1.03M | Buy |
88,600
+850
| +1% | +$10K | 0.62% | 49 |
|
|
2021
Q3 | $1.19M | Buy |
+87,750
| New | +$1.17M | 0.74% | 47 |
|
Other funds holding XGN
Penbrook Management's XGN Position: Q3 2026 in Review
Penbrook Management opened a new position in Exagen (XGN) in Q3 2026: 11,300 shares worth $91.9K. The stake represents 0.05% of the portfolio and ranks #100 among its holdings. This is a return to the name: Penbrook Management previously reported a position in XGN as recently as Q1 2026.
Penbrook Management first reported a position in XGN in Q3 2021 and has held it in 20 quarters since. The position peaked at $1.19M in Q3 2021. 2 funds tracked by Wall St. Rank hold XGN as of Q3 2026.
- Penbrook Management held 11,300 shares of Exagen worth $91.9K as of Q3 2026.
- Exagen was a new Penbrook Management position in Q3 2026.
- Exagen made up 0.05% of Penbrook Management's portfolio in Q3 2026, its #100 holding.
- Penbrook Management first reported a position in Exagen in Q3 2021 and has held it in 20 quarters since.
- Penbrook Management's Exagen position peaked at $1.19M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Exagen as of Q3 2026.
Based on Penbrook Management's 13F filing for Q3 2026, filed 16 Oct 2026.